GLOBEALERT
Business● LowSep 24 · Sep 24, 2026, 2:26 PM

Arcturus raised to Buy at Citi after mid-stage trial data for liver disease drug

GlobeAlert Desk · curated from Seeking Alpha Tech · global

Citi has upgraded Arcturus's stock rating to "Buy" following the release of mid-stage trial data for its liver disease drug. This indicates a positive outlook on the company's pharmaceutical development and market performance.

GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.

GlobeAlert context

What the desk knows about this story

Threat level
0 Low

Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.

Sources
1 publisher

Single-source so far. Treat details as unconfirmed until more publishers report.

Category
Business

Not flagged as developing.

More in Business